Explore the DealMatrix Industry Multiple for HealthTech: EV/Sales and EV/EBITDA across all regions.
HealthTech companies digitise care delivery, diagnostics, and patient engagement with software and connected devices. Private-market valuations reflect clinical validation, payer or provider distribution, and the share of recurring, reimbursable revenue.
The category spans digital therapeutics, care-delivery platforms, remote monitoring, and health data infrastructure.
Sector
Health & Life Sciences
Sector tracked since
2000
25+ years of data
EV/SALES & EV/EBITDA FOR
All Regions
Modelled independently via proprietary econometric approach
UPDATE FREQUENCY
Quarterly
Data updates & model improvement
Derived from listed-company data through the DealMatrix model and industry mapping, before stage adjustment.
A Series A HealthTech company in Europe is priced differently. Get the DealMatrix Multiple for your stage and region.
Run HealthTech for your stage and region →DealMatrix multiples are proprietary private-market benchmarks, derived through a six-step model that translates public capital-market index comparables into private-market segments and funding stages, adjusted for macroeconomic conditions.
The model produces three components: The reported public multiple, the model-predicted multiple, and the lower bound predicted multiple averaged into the DealMatrix Composite, then adjusted for region and funding stage. The methodology follows the IPEV Guidelines 2025.
raised
Valuation
raised
Valuation
raised
Valuation
Region
Stage
raised
Valuation
raised
Valuation
raised
Valuation
Valuation benchmarks differ across industries as business models, growth rates and margins vary. Explore the sectors most related to HealthTech to see how their EV/Sales and EV/EBITDA multiples compare.
What is the valuation multiple for HealthTech companies?
As of 31 December 2025, the DealMatrix Industry Multiple for HealthTech across all regions is 5.1× EV/Sales and 23.4× EV/EBITDA. It is derived from listed-company data through the DealMatrix model and industry mapping, before stage adjustment.
Why does a HealthTech company at my stage or in my region get a different multiple?
The industry multiple covers all regions and is shown before stage adjustment. A Series A HealthTech company in Europe is priced differently. The DealMatrix platform gives the multiple for your stage and region.
What is the difference between EV/Sales and EV/EBITDA for HealthTech?
EV/Sales (enterprise value ÷ revenue) is used for high-growth HealthTech companies that are not yet profitable, while EV/EBITDA (enterprise value ÷ operating profit) applies to mature, profitable ones. Early-stage companies are usually benchmarked on EV/Sales.
How is the HealthTech industry multiple calculated?
It is derived from listed-company data through the DealMatrix model and industry mapping. The methodology follows the IPEV Guidelines 2025.
How current is this HealthTech figure?
The figure shown is as of 31 December 2025. Current-quarter figures are available in the DealMatrix platform.